MannKind (NASDAQ:MNKD) Stock Price Target Raised at Cantor Fitzgerald

MannKind (NASDAQ:MNKD) had its price objective increased by research analysts at Cantor Fitzgerald from $8.00 to $10.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald‘s price target would suggest a potential upside of 165.96% from the company’s previous close.

Other analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating on shares of MannKind in a research note on Thursday, July 23rd. Zacks Research raised MannKind from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of MannKind in a report on Friday, October 2nd. Wall Street Zen cut MannKind from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Chardan Capital assumed coverage on shares of MannKind in a research note on Monday, October 19th. They issued a “buy” rating and a $10.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, MannKind currently has an average rating of “Moderate Buy” and a consensus price target of $8.31.

MannKind Price Performance

MannKind stock opened at $3.76 on Friday. MannKind has a fifty-two week low of $2.23 and a fifty-two week high of $6.51. The firm has a fifty day moving average price of $3.55 and a two-hundred day moving average price of $3.72. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -28.92 and a beta of 1.10.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.05. The business had revenue of $101.87 million during the quarter, compared to analyst estimates of $107.74 million. The company’s revenue for the quarter was up 24.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.03 earnings per share. As a group, sell-side analysts expect that MannKind will post -0.21 earnings per share for the current year.

Insider Buying and Selling at MannKind

In other news, Director Steven Binder sold 39,051 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $3.29, for a total transaction of $128,477.79. Following the sale, the director directly owned 713,258 shares in the company, valued at approximately $2,346,618.82. The trade was a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On MannKind

Several hedge funds and other institutional investors have recently modified their holdings of MNKD. Wellington Management Group LLP raised its stake in shares of MannKind by 138.9% in the second quarter. Wellington Management Group LLP now owns 7,844,807 shares of the biopharmaceutical company’s stock valued at $33,419,000 after acquiring an additional 4,561,628 shares during the last quarter. Braidwell LP bought a new stake in MannKind during the 2nd quarter worth approximately $14,733,000. 180 Wealth Advisors LLC grew its position in MannKind by 45.0% during the 1st quarter. 180 Wealth Advisors LLC now owns 4,291,703 shares of the biopharmaceutical company’s stock worth $10,515,000 after acquiring an additional 1,332,759 shares during the last quarter. Bank of America Corp DE increased its holdings in MannKind by 43.2% during the 1st quarter. Bank of America Corp DE now owns 3,383,677 shares of the biopharmaceutical company’s stock valued at $8,290,000 after purchasing an additional 1,021,456 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in MannKind during the 2nd quarter valued at $3,827,000. Institutional investors own 49.55% of the company’s stock.

Key Headlines Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: MannKind said it expects about $1 billion in revenue from its United Therapeutics deal over 2027–2030 and is targeting profitability in the fourth quarter. Those milestones could support the longer-term outlook if achieved. Article: MannKind anticipates $1B in revenue from United Therapeutics deal
• Positive Sentiment: Third-quarter revenue rose 24% year over year, and one reported earnings comparison showed a smaller loss than analysts expected. Analysts’ consensus target price was reported at $8.08, suggesting favorable analyst expectations, though targets are not guarantees. Article: MannKind consensus target price
• Negative Sentiment: Quarterly revenue of $101.9 million fell short of the roughly $107.7 million consensus, while the company remained loss-making. The revenue miss and ongoing losses may be weighing on shares despite year-over-year growth and the forward-looking targets. Article: MannKind Reports Third Quarter 2026 Financial Results

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).